Cost-effectiveness of minimally invasive weight loss treatments compared to sleeve stomach surgery and semaglutide

Declarations. Ethical Approval: Ethical approval for the use of CPRD data was granted by the Independent Scientific Advisory Committee (IASC) (protocol no. 22_002470). Consent: Individual patient consent was not required as anonymized data were used in accordance with CPRD governance procedures. Competing Interests: Ken Clare (KC) has received funding from industry. KC is a member of the Patient Advisory Board Novo Nordisk, Patient Advisory Board Boehringer Ingelheim and has received consulting fees from Eli Lilly. KC has membership of IHCOM board, was a Trustee ASO (resigned September 2023) and is Director of Operations Obesity UK, Chair of European Coalition of People Living with Obesity and Chair of WLSinfo Charity. Abd Tahrani (AT) has received funding from industry. At the time of writing this paper, AT was an employee and shareholder of Novo Nordisk. This work was funded before AT became a Novo Nordisk employee and Novo Nordisk has no role in this project. The views expressed in this report are those of the authors and not those of Novo Nordisk. AT currently is an employee of Amgen Research Copenhagen (ARC). ARC had no role in this project or this manuscript. Emma Frew (EF) has received funding from industry and has received consulting fees from Novo Nordisk. She has received consulting fees from UK local and regional government. EF has Membership of NIHR-funded trial steering committees, was an Elected Board member for the International Health Economics Association, a Trustee for the Association for Study of Obesity, and is a member of the strategic advisory council for the APPG-obesity. No conflicts of interest were declared by other authors.